ASCLETIS-B (01672) announced that it will present data from its ASC30 oral small molecule GLP-1 receptor (GLP-1R) agonist 28-day multiple ascending dose study (NCT06680440) during a brief oral presentation session at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.

"We look forward to presenting clinical data for ASC30 oral tablets to the industry at this year's EASD Annual Meeting," said Dr. Wu Jinzi, Founder, Chairman and Chief Executive Officer of Ascletis. "We believe these efficacy and safety data will position ASC30 oral tablets as a promising differentiated treatment option for obesity."

ASC30 is a small molecule GLP-1R biased agonist currently under clinical investigation, featuring unique and differentiated properties that enable the same small molecule to be suitable for both oral tablet and subcutaneous injection administration. ASC30 is a new chemical entity (NCE) with U.S. and global compound patent protection, with patent protection extending until 2044 (excluding patent extensions).